Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-19 |
MYLAN Dec-18 |
ABBOTT INDIA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,834 | 3,470 | - | |
Low | Rs | 5,458 | 1,910 | - | |
Sales per share (Unadj.) | Rs | 1,731.1 | 1,596.7 | - | |
Earnings per share (Unadj.) | Rs | 211.9 | 43.4 | - | |
Cash flow per share (Unadj.) | Rs | 219.9 | 342.3 | - | |
Dividends per share (Unadj.) | Rs | 65.00 | 0 | - | |
Dividend yield (eoy) | % | 0.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 945.2 | 1,727.4 | - | |
Shares outstanding (eoy) | m | 21.25 | 514.50 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.1 | 1.7 | 245.0% | |
Avg P/E ratio | x | 33.7 | 62.0 | 54.3% | |
P/CF ratio (eoy) | x | 32.5 | 7.9 | 413.6% | |
Price / Book Value ratio | x | 7.6 | 1.6 | 485.5% | |
Dividend payout | % | 30.7 | 0 | - | |
Avg Mkt Cap | Rs m | 151,848 | 1,384,010 | 11.0% | |
No. of employees | `000 | 3.5 | 35.0 | 10.0% | |
Total wages/salary | Rs m | 4,356 | 0 | - | |
Avg. sales/employee | Rs Th | 10,555.5 | 23,471.7 | 45.0% | |
Avg. wages/employee | Rs Th | 1,249.9 | 0 | - | |
Avg. net profit/employee | Rs Th | 1,292.2 | 637.4 | 202.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,786 | 821,510 | 4.5% | |
Other income | Rs m | 1,133 | 0 | - | |
Total revenues | Rs m | 37,919 | 821,510 | 4.6% | |
Gross profit | Rs m | 6,047 | 212,576 | 2.8% | |
Depreciation | Rs m | 169 | 153,819 | 0.1% | |
Interest | Rs m | 23 | 39,512 | 0.1% | |
Profit before tax | Rs m | 6,989 | 19,246 | 36.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,485 | -3,062 | -81.2% | |
Profit after tax | Rs m | 4,503 | 22,307 | 20.2% | |
Gross profit margin | % | 16.4 | 25.9 | 63.5% | |
Effective tax rate | % | 35.6 | -15.9 | -223.5% | |
Net profit margin | % | 12.2 | 2.7 | 450.8% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,610 | 458,731 | 6.0% | |
Current liabilities | Rs m | 8,569 | 334,465 | 2.6% | |
Net working cap to sales | % | 51.8 | 15.1 | 342.2% | |
Current ratio | x | 3.2 | 1.4 | 234.9% | |
Inventory Days | Days | 60 | 84 | 72.0% | |
Debtors Days | Days | 27 | 93 | 29.4% | |
Net fixed assets | Rs m | 1,057 | 159,359 | 0.7% | |
Share capital | Rs m | 213 | 437 | 48.6% | |
Net worth | Rs m | 20,086 | 888,724 | 2.3% | |
Long term debt | Rs m | 0 | 959,218 | 0.0% | |
Total assets | Rs m | 29,409 | 2,383,903 | 1.2% | |
Interest coverage | x | 311.6 | 1.5 | 20,953.7% | |
Debt to equity ratio | x | 0 | 1.1 | 0.0% | |
Sales to assets ratio | x | 1.3 | 0.3 | 363.0% | |
Return on assets | % | 15.4 | 2.6 | 593.4% | |
Return on equity | % | 22.4 | 2.5 | 893.2% | |
Return on capital | % | 34.9 | 3.2 | 1,097.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,991 | 170,710 | 2.9% | |
From Investments | Rs m | -2,570 | -88,238 | 2.9% | |
From Financial Activity | Rs m | -1,428 | -79,527 | 1.8% | |
Net Cashflow | Rs m | 993 | 1,414 | 70.2% |
Compare ABBOTT INDIA With: ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Compare ABBOTT INDIA With: NOVARTIS SANOFI INDIA DISHMAN PHARMA LUPIN DR. REDDYS LAB
Indian share markets witnessed huge selling during closing hours today and ended their day lower.
For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
An Indian company founded three decades ago in a garage caught my attention...
In this video, I'll show you how to allocate your capital as a day trader.
More